Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

9 recruiting

Enrollment Performance

Analytics

Phase 1
8(88.9%)
N/A
1(11.1%)
9Total
Phase 1(8)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT06326021Phase 1Recruiting

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Role: collaborator

NCT06343090Not ApplicableRecruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Role: collaborator

NCT06316856Phase 1Recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Role: collaborator

NCT07070323Phase 1Recruiting

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

Role: collaborator

NCT07003568Phase 1Recruiting

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Role: collaborator

NCT06316427Phase 1Recruiting

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies

Role: collaborator

NCT07003555Phase 1Recruiting

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Role: collaborator

NCT07022964Phase 1Recruiting

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

Role: collaborator

NCT06925464Phase 1Recruiting

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

Role: collaborator

All 9 trials loaded